Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma

This article was originally published in The Pink Sheet Daily

Executive Summary

SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.

You may also be interested in...



Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Just days after Seattle Genetics lost Roche/Genentech as a partner for dacetuzumab (SGN-40), a CD40 antibody in development for lymphomas and multiple myeloma, the company has a new Big Pharma partner to head into the new year with. Seattle Genetics and Takeda's Millennium oncology unit announced a licensing deal Dec. 15 for brentuximab vedotin (SGN-35), an antibody-drug conjugate in development for lymphomas

Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.

Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel